摘要
目的探讨胃复春片联合埃索美拉唑治疗慢性萎缩性胃炎的临床疗效。方法选择该院2018年1月—2019年1月收治的70例慢性萎缩性胃炎患者作为研究对象,采用随机数表法分为两组,各35例。对照组给予含埃索美拉唑的四联疗法治疗,观察组在对照组基础上给予胃复春片。比较两组炎症因子水平、氧化应激水平及不良反应发生率。结果观察组治疗后肿瘤坏死因子-α(TNF-α)[(21.93±1.08)pg/mL]、白细胞介素-8(IL-8)[(10.47±1.62)pg/mL]及白细胞介素-6(IL-6)[(6.41±0.97)pg/mL]水平均低于对照组[(30.79±1.94)pg/mL、(16.94±1.81)pg/mL、(11.72±1.13)pg/mL],差异有统计学意义(t=23.607、15.758、21.094,P<0.05);观察组治疗后超氧化物歧化酶(SOD)水平[(91.67±7.06)U/mL]及一氧化氮(NO)水平[(42.59±5.36)μmoL/L]均高于对照组[(85.13±6.94)U/mL、(35.42±5.79)μmoL/L],差异有统计学意义(t=3.908、5.376,P<0.05);两组治疗期间不良反应发生率比较(8.57%、14.29%),差异无统计学意义(χ^2=0.141,P=0.452)。结论胃复春片联合埃索美拉唑治疗慢性萎缩性胃炎的安全性高,可减轻炎症反应,改善氧化应激水平,促使患者疾病转归。
Objective To explore the clinical effect of Weifuchun tablets combined with esomeprazole on chronic atrophic gastritis.Methods Seventy patients with chronic atrophic gastritis admitted in the hospital from January 2018 to January 2019 were selected as the research object,and were divided into two groups with random number table method,35 cases in each.The control group was given quadruple therapy with esomeprazole,and the observation group was given Weifuchun tablets based on the control group.The levels of inflammatory factors,oxidative stress and the incidence of adverse reactions were compared between the two groups.Results After treatment,the tumor necrosis factor-α(TNF-α)[(21.93±1.08)pg/mL],interleukin-8(IL-8)[(10.47±1.62)pg/mL]and interleukin-6(IL-6)[(6.41±0.97)pg/mL]level,lower than the control group[(30.79±1.94)pg/mL,(16.94±1.81)pg/mL,(11.72±1.13)pg/m L],the difference was statistically significant(t=23.607,15.758,21.094,P<0.05);the level of superoxide dismutase(SOD)in the observation group after treatment[(91.67±7.06)U/mL]and nitric oxide(NO)levels[(42.59±5.36)μmoL/L],higher than the control group[(85.13±6.94)U/mL,(35.42±5.79)μmoL/L],the difference was statistically significant(t=3.908,5.376,P<0.05);the incidence of adverse reactions during the treatment between the two groups(8.57%,14.29%),the difference was not statistically significant(χ^2=0.141,P=0.452).Conclusion Weifuchun tablets combined with esomeprazole have high safety in the treatment of chronic atrophic gastritis,which can reduce the inflammatory response,improve the level of oxidative stress,and promote the patients’disease outcome.
作者
王维国
WANG Wei-guo(Department of Gastroenterology,Dezhou Municipal Hospital,Dezhou,Shandong Province,253000 China)
出处
《世界复合医学》
2020年第6期178-180,共3页
World Journal of Complex Medicine
关键词
慢性萎缩性胃炎
胃复春片
埃索美拉唑
炎症因子
氧化应激
Chronic atrophic gastritis
Weifuchun tablets
Esomeprazole
Inflammatory factors
Oxidative stress
